STAAR Surgical Stock Rises 17.8% Following Strong Preliminary Q1 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy STAA?
Source: moomoo
- Company Performance: STAR Surgical shares have surged by 17.8% following a strong preliminary Q1 performance.
- Market Reaction: The increase in share value indicates positive investor sentiment and confidence in the company's growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STAA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STAA
Wall Street analysts forecast STAA stock price to rise
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 25.080
Low
30.75
Averages
30.75
High
30.75
Current: 25.080
Low
30.75
Averages
30.75
High
30.75
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
STAAR Surgical Q1 2026 Sales Exceed Expectations, Upgraded to Buy
- Sales Performance Exceeds Expectations: STAAR Surgical estimates Q1 2026 net sales will surpass $90 million, exceeding the consensus of $67.6 million by over 100%, indicating strong year-over-year growth that reflects the company's competitive position and rising product demand.
- Analyst Rating Upgrade: Canaccord Genuity upgraded STAAR's rating from Hold to Buy and raised its price target from $22 to $27, primarily based on the stock's compelling valuation and momentum in the China market, demonstrating confidence in the company's future performance.
- Distributor Dynamics Impact: Analysts noted that part of STAAR's sales growth is attributed to restocking by distributors following the termination of a merger agreement with Swiss rival Alcon, suggesting that this dynamic may influence future sales strategies and market share.
- Chinese Market Potential: While Q2 is typically the largest revenue quarter for China, analysts caution that the terminated acquisition may alter distributor dynamics, which could significantly impact STAAR's sales performance, necessitating close monitoring of market changes.
See More
Stock Price Movements of Various Companies
- Revenue Miss: Simply Good Foods' stock fell 19% after its fiscal second-quarter revenue and adjusted EBITDA significantly missed Wall Street consensus, indicating investor concerns about future growth and potentially impacting market confidence.
- Acquisition Potential: Brown-Forman's shares surged 12% following reports that Sazerac is approaching the company for a potential deal, reflecting market optimism regarding its merger prospects, which could enhance long-term value.
- Tech Stocks Under Pressure: Software stocks declined for the second consecutive day, with the iShares Expanded Tech-Software Sector ETF dropping nearly 4%, highlighting investor concerns over AI-related risks that may weaken confidence in tech equities.
- Strong Earnings Guidance: Staar Surgical's stock jumped about 27% after guiding for first-quarter revenue exceeding $90 million, well above the $67.6 million expected by analysts, showcasing the company's robust performance and growth potential in the market.
See More
STAAR Surgical Stock Rises 17.8% Following Strong Preliminary Q1 Results
- Company Performance: STAR Surgical shares have surged by 17.8% following a strong preliminary Q1 performance.
- Market Reaction: The increase in share value indicates positive investor sentiment and confidence in the company's growth prospects.
See More
Major Moves in Premarket Trading by Various Companies
- Datadog Stock Rise: Datadog shares increased by 2.3% after Guggenheim upgraded its rating from neutral to buy, with analysts believing the company will benefit from AI-driven growth in data volumes and IT complexity.
- CoreWeave Infrastructure Expansion: CoreWeave's stock surged over 5% following the announcement of a $21 billion infrastructure deal with Meta Platforms, which aims to optimize performance and scalability for Meta's AI operations.
- Constellation Brands Guidance Withdrawal: Constellation Brands saw its shares dip less than 1% after withdrawing its 2028 guidance due to subdued demand, despite reporting fourth-quarter results that exceeded market expectations.
- Airlines Stock Fluctuation: Rising oil prices led to a decline in airline stocks, with Alaska Air dropping approximately 2%, while United Airlines, American Airlines, and Delta Air Lines each fell by 1%.
See More
Stock Market Movers: Nvidia, Chevron, Applied Digital, Staar Surgical, and Others
- Market Outlook: U.S. stocks are expected to experience small losses on Thursday.
- Geopolitical Concerns: Uncertainty surrounds the durability of a two-week truce with Iran, contributing to market apprehension.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
STAAR Surgical Q1 2026 Sales Exceed Expectations, Upgraded to Buy
- Sales Performance Exceeds Expectations: STAAR Surgical estimates Q1 2026 net sales will surpass $90 million, exceeding the consensus of $67.6 million by over 100%, indicating strong year-over-year growth that reflects the company's competitive position and rising product demand.
- Analyst Rating Upgrade: Canaccord Genuity upgraded STAAR's rating from Hold to Buy and raised its price target from $22 to $27, primarily based on the stock's compelling valuation and momentum in the China market, demonstrating confidence in the company's future performance.
- Distributor Dynamics Impact: Analysts noted that part of STAAR's sales growth is attributed to restocking by distributors following the termination of a merger agreement with Swiss rival Alcon, suggesting that this dynamic may influence future sales strategies and market share.
- Chinese Market Potential: While Q2 is typically the largest revenue quarter for China, analysts caution that the terminated acquisition may alter distributor dynamics, which could significantly impact STAAR's sales performance, necessitating close monitoring of market changes.
See More
Stock Price Movements of Various Companies
- Revenue Miss: Simply Good Foods' stock fell 19% after its fiscal second-quarter revenue and adjusted EBITDA significantly missed Wall Street consensus, indicating investor concerns about future growth and potentially impacting market confidence.
- Acquisition Potential: Brown-Forman's shares surged 12% following reports that Sazerac is approaching the company for a potential deal, reflecting market optimism regarding its merger prospects, which could enhance long-term value.
- Tech Stocks Under Pressure: Software stocks declined for the second consecutive day, with the iShares Expanded Tech-Software Sector ETF dropping nearly 4%, highlighting investor concerns over AI-related risks that may weaken confidence in tech equities.
- Strong Earnings Guidance: Staar Surgical's stock jumped about 27% after guiding for first-quarter revenue exceeding $90 million, well above the $67.6 million expected by analysts, showcasing the company's robust performance and growth potential in the market.
See More
STAAR Surgical Stock Rises 17.8% Following Strong Preliminary Q1 Results
- Company Performance: STAR Surgical shares have surged by 17.8% following a strong preliminary Q1 performance.
- Market Reaction: The increase in share value indicates positive investor sentiment and confidence in the company's growth prospects.
See More
Major Moves in Premarket Trading by Various Companies
- Datadog Stock Rise: Datadog shares increased by 2.3% after Guggenheim upgraded its rating from neutral to buy, with analysts believing the company will benefit from AI-driven growth in data volumes and IT complexity.
- CoreWeave Infrastructure Expansion: CoreWeave's stock surged over 5% following the announcement of a $21 billion infrastructure deal with Meta Platforms, which aims to optimize performance and scalability for Meta's AI operations.
- Constellation Brands Guidance Withdrawal: Constellation Brands saw its shares dip less than 1% after withdrawing its 2028 guidance due to subdued demand, despite reporting fourth-quarter results that exceeded market expectations.
- Airlines Stock Fluctuation: Rising oil prices led to a decline in airline stocks, with Alaska Air dropping approximately 2%, while United Airlines, American Airlines, and Delta Air Lines each fell by 1%.
See More
Stock Market Movers: Nvidia, Chevron, Applied Digital, Staar Surgical, and Others
- Market Outlook: U.S. stocks are expected to experience small losses on Thursday.
- Geopolitical Concerns: Uncertainty surrounds the durability of a two-week truce with Iran, contributing to market apprehension.
See More
